Stephen Davis, CEO at ACADIA PHARMACEUTICALS INC (ACAD), sold 126,706 shares at $25.00 ($3.2M) on 2023-07-11, disclosed to the SEC on 2023-07-13.
Scheduled sale ($3.2M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 16,498 | $412K | 13.0% |
| 2 | $25.05 | 55,104 | $1.4M | 43.5% |
| 3 | $25.05 | 55,104 | $1.4M | 43.5% |
| Total | $25.04 avg | 126,706 | $3.2M | 100% |
| Filing → |
| ACAD | SELL | 2024-04-09 | $950K | — | Filing → |
| ACAD | SELL | 2024-03-27 | $634K | — | Filing → |
| ACAD | SELL | 2024-02-27 | $275K | — | Filing → |